# Is Johnson & Johnson (JNJ) a Buy? — 2026 Fundamental Analysis

> Leans Hold — Defensive healthcare anchor. Johnson & Johnson screens as a Hold-to-accumulate: reasonable valuation and elite dividend quality balanced against modest growth and litigation overhangs.

**Bottom line (2026-07-14):** Johnson & Johnson (JNJ) screens as a Hold on FolioFundamentals' 5-Pillar Fundamental Score (0–100, 23 data points, sector-normalized). The exact live score and entry price are computed at https://foliofundamentals.com/analyzer?s=JNJ

## What JNJ does
Johnson & Johnson is a diversified healthcare leader spanning innovative pharmaceuticals and medical technology (following the Kenvue consumer-health spin-off), with a broad drug pipeline and device franchise.

## 5-Pillar Fundamental Score read

| Pillar | JNJ reads as | Why |
|--------|------|-----|
| Valuation | Reasonable | JNJ typically trades at a fair multiple for its stability, so the Valuation pillar scores respectably. |
| Cash Flow Quality | Strong | Diversified healthcare cash flows are deep and dependable, supporting a solid Cash Flow Quality score. |
| Growth Momentum | Modest | Low-to-mid single-digit growth keeps the Growth pillar restrained; this is a stability holding. |
| Analyst Consensus | Hold to Buy | Consensus is steady but not aggressive, giving the Analyst pillar a middling contribution. |
| Price-Target Upside | Modest upside | Targets usually sit near the current price, so the Price-Target pillar adds little. |

## Bull case
- A diversified pharma-plus-medtech model reduces reliance on any single drug or device.
- A Dividend King with 60-plus years of consecutive increases and a fortress balance sheet.
- Defensive, recession-resistant demand for healthcare products and therapies.

## Bear case
- Ongoing talc and other litigation creates a hard-to-quantify liability overhang.
- Patent cliffs on key drugs require the pipeline to continually replace expiring revenue.
- Growth is modest, so total return leans heavily on the dividend and buybacks.

## Entry point
JNJ's Valuation pillar and dividend yield tend to look best when litigation headlines or patent-cliff worries push the stock down. Because the underlying cash flows are so stable, those fear-driven de-ratings have historically been the more rewarding entry points for long-term holders.

## Dividend
A cornerstone income holding — a Dividend King with 60+ years of increases, an attractive yield, and one of the few AAA-adjacent balance sheets backing it.

## See the live score
Full 0–100 Fundamental Score, entry point, 30-year valuation history and 13F institutional holdings for JNJ: https://foliofundamentals.com/analyzer?s=JNJ

_Informational/educational only — not investment advice. The Fundamental Score is a quantitative starting point, not a buy/sell recommendation._